TX-PLANVIEW
Planview ®, the global leader in Portfolio Management and Work Management, today announced the acquisition of Enrich , a product portfolio analytics company that empowers R&D organizations with complex portfolios to make strategic business decisions in real-time.
"As product portfolios continue to expand, companies are making big bets on business initiatives that can cost millions of dollars and take years to see to completion,” said Razat Gaurav, Chief Executive Officer at Planview. “Enrich brings deep expertise in complex product prioritization and data science techniques supporting portfolio decision-making, allowing companies to make more confident and insight-driven decisions on the investments that will achieve the greatest impact.”
“Enrich and Planview share a similar commitment: enabling our customers to achieve their most critical outcomes,” said Dr. Rich Sonnenblick, Founder and Chief Executive Officer at Enrich. “Over the last 24 years, we’ve worked with more than half of the leading life sciences companies globally to provide real-time visibility into the current and future health of their product pipelines, allowing them to make better investment decisions and align with business goals. We are looking forward to joining the Planview team and bringing our best-in-class simulation and analytics capabilities to Planview customers.”
Founded by Sonnenblick following his PhD from Carnegie Mellon University, Enrich provides a secure, cloud-based platform for portfolio prioritization, valuation, and scenario analysis using a tailored and flexible analytics engine seamlessly connected to a flexible visualization layer. The company’s emphasis is on establishing best-in-class, self-sufficient, strategic portfolio capabilities in every customer they work with.
Enrich’s Sonnenblick and his team of data scientists will join Planview, further deepening Planview’s data science and analytics expertise. Sonnenblick will serve as Planview’s Chief Data Scientist, focused on building and expanding the company’s data science initiatives and delivering predictive and prescriptive insights for Planview solutions.
Combining Enrich with Planview deepens the company’s commitment to product portfolio management and helping customers realize the future of connected work to accelerate the achievement of what matters most.
This acquisition closely follows the company’s announcement of its intent to acquire Tasktop , which is expected to close in Q3 of 2022.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com .
About Enrich Consulting
Founded in 1998, Enrich provides flexible analytics, scenario planning, simulation, and optimization techniques tailored for R&D teams to enable portfolio planning and prioritization, decision support, and risk analysis for highly-complex product portfolios. Leading Pharmaceutical and Life Sciences brands, including half of the top 20 life sciences companies, use Enrich to provide real-time visibility into the health of product portfolios, allowing them to make better decisions and align with business goals. For more information, visit: https://www.enrichconsulting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006173/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting konsoliderer sit udbud inden for digital transformation med tilføjelsen af Internet & Idee22.1.2026 14:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Internet & Idee, et italiensk digitalt konsulentbureau, og styrker dermed sin evne til at levere integrerede, teknologidrevne løsninger. Internet & Idee blev stiftet i 1998 og specialiserer sig i digital strategi, softwareudvikling, test og kvalitetssikring, e-handel og mobile løsninger. Virksomheden opererer inden for to kerneområder: It-konsulentydelser og egne SaaS-produkter, herunder værktøjer til kreditstyring og cybersikkerhed. Med dyb ekspertise inden for bankvæsen, forsikring, kreditstyring og logistik for e-handel kombinerer Internet & Idee brancheindsigt med teknisk innovation med henblik på at drive forretningsresultater. "Dette samarbejde giver os mulighed for at anvende vores digitale ekspertise og branchekendskab i større skala," udtaler Carlo Stumpo, administrerende direktør for Internet & Idee. "Sammen med Andersen Consulting kan vi levere mere målrettede og effektive løsninger til kunder, der står over for komplekse ud
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release
Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax
ExaGrid Announces All Flash/SSD Tiered Backup Storage Solution22.1.2026 14:00:00 CET | Press release
ExaGrid’s new solution offers the fastest, most scalable, and most secure backups in the industry ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it is shipping an All Flash/SSD backup storage solution with a unique front-end Landing Zone and non-network-facing Repository Tier (tiered air gap) that stores all backup retention using advanced data deduplication. The new SSD appliances ship with ExaGrid software version 8. ExaGrid’s unique Landing Zone and scale-out architecture allow for significantly faster backups and restores, as well as scalability as data grows, versus other SSD products such as Dell Data Domain inline deduplication appliances with SSD or straight SSD from Pure Storage. Due to three years of software work and the extremely fast performance of SSD, ExaGrid’s
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis22.1.2026 14:00:00 CET | Press release
New Trailmaker functionality integrates immune repertoire and whole transcriptome data to deliver rapid, publication-ready insights Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker™. The new functionality complements Parse’s existing portfolio of Evercode immune products to enable a full end-to-end workflow for researchers. Immunologists have lacked an integrated, purpose-built platform capable of connecting immune repertoire data with whole transcriptome single cell insights. As a result, interpreting clonal behavior, understanding functional cell states, and drawing meaningful biological conclusions has often required stitching together fragmented tools, custom code, or inconsistent visualization approaches. The new Trailmaker functionality directly addresses these challenges by provi
AMGTA Announces EOS as New Principal Member and Appoints Björn Hannappel to Board of Directors22.1.2026 13:59:00 CET | Press release
The Additive Manufacturer Green Trade Association (AMGTA) today announced that EOS has elevated its longstanding participation in the association to Principal Member. As part of this expanded leadership role, Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121601881/en/ Björn Hannappel, Head of Sustainability at EOS, has joined the AMGTA Board of Directors. Principal Membership represents AMGTA’s highest level of engagement and is reserved for organizations demonstrating sustained leadership, strategic alignment, and a commitment to advancing sustainable and resilient manufacturing practices globally. As a Principal Member, EOS will take on an expanded role in shaping AMGTA’s strategic direction, governance, and industry collaboration initiatives. EOS is a world-leading technology supplier in the field of commercial 3D printing of meta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom